Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency.

Taraldsrud E, Aukrust P, Jørgensen S, Lingjærde OC, Olweus J, Myklebust JH, Fevang B.

Clin Immunol. 2017 Feb;175:69-74. doi: 10.1016/j.clim.2016.11.014.

PMID:
27919819
2.

A systematic comparison of copy number alterations in four types of female cancer.

Kaveh F, Baumbusch LO, Nebdal D, Børresen-Dale AL, Lingjærde OC, Edvardsen H, Kristensen VN, Solvang HK.

BMC Cancer. 2016 Nov 22;16(1):913.

3.

The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma.

Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH.

Cancer Res. 2016 Sep 1;76(17):5092-102. doi: 10.1158/0008-5472.CAN-16-0658.

PMID:
27488532
4.

Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.

Sveen A, Løes IM, Alagaratnam S, Nilsen G, Høland M, Lingjærde OC, Sorbye H, Berg KC, Horn A, Angelsen JH, Knappskog S, Lønning PE, Lothe RA.

PLoS Genet. 2016 Jul 29;12(7):e1006225. doi: 10.1371/journal.pgen.1006225. eCollection 2016 Jul 29.

5.

Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes.

Haukaas TH, Euceda LR, Giskeødegård GF, Lamichhane S, Krohn M, Jernström S, Aure MR, Lingjærde OC, Schlichting E, Garred Ø, Due EU, Mills GB, Sahlberg KK, Børresen-Dale AL, Bathen TF; Oslo Breast Cancer Consortium (OSBREAC)..

Cancer Metab. 2016 Jun 27;4:12. doi: 10.1186/s40170-016-0152-x.

6.

The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB.

Br J Haematol. 2016 Oct;175(1):102-14. doi: 10.1111/bjh.14201.

PMID:
27341313
7.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676.

8.

Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma.

Sandhu V, Bowitz Lothe IM, Labori KJ, Skrede ML, Hamfjord J, Dalsgaard AM, Buanes T, Dube G, Kale MM, Sawant S, Kulkarni-Kale U, Børresen-Dale AL, Lingjærde OC, Kure EH.

Mol Oncol. 2016 Feb;10(2):303-16. doi: 10.1016/j.molonc.2015.10.011.

9.

Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma.

Hamfjord J, Saldova R, Stöckmann H, Sandhu V, Bowitz Lothe IM, Buanes T, Lingjærde OC, Labori KJ, Rudd PM, Kure EH.

J Proteome Res. 2015 Dec 4;14(12):5144-56. doi: 10.1021/acs.jproteome.5b00395.

PMID:
26515733
10.

Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN.

Borge KS, Nord S, Van Loo P, Lingjærde OC, Gunnes G, Alnæs GI, Solvang HK, Lüders T, Kristensen VN, Børresen-Dale AL, Lingaas F.

PLoS One. 2015 May 8;10(5):e0126371. doi: 10.1371/journal.pone.0126371.

11.

Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.

Tinholt M, Vollan HK, Sahlberg KK, Jernström S, Kaveh F, Lingjærde OC, Kåresen R, Sauer T, Kristensen V, Børresen-Dale AL, Sandset PM, Iversen N.

Breast Cancer Res. 2015 Mar 26;17:44. doi: 10.1186/s13058-015-0548-5.

12.

Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer.

Aure MR, Jernström S, Krohn M, Vollan HK, Due EU, Rødland E, Kåresen R; Oslo Breast Cancer Research Consortium (OSBREAC)., Ram P, Lu Y, Mills GB, Sahlberg KK, Børresen-Dale AL, Lingjærde OC, Kristensen VN.

Genome Med. 2015 Feb 2;7(1):21. doi: 10.1186/s13073-015-0135-5.

13.

Glycan-related gene expression signatures in breast cancer subtypes; relation to survival.

Potapenko IO, Lüders T, Russnes HG, Helland Å, Sørlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD.

Mol Oncol. 2015 Apr;9(4):861-76. doi: 10.1016/j.molonc.2014.12.013.

14.

Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas.

Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH.

Mol Oncol. 2015 Apr;9(4):758-71. doi: 10.1016/j.molonc.2014.12.002.

15.

The multitude of molecular analyses in cancer: the opening of Pandora’s box.

Russnes HG, Lønning PE, Børresen-Dale AL, Lingjærde OC.

Genome Biol. 2014;15(9):447.

16.

A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN; METABRIC Group., Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C.

Mol Oncol. 2015 Jan;9(1):115-27. doi: 10.1016/j.molonc.2014.07.019.

17.

Principles and methods of integrative genomic analyses in cancer.

Kristensen VN, Lingjærde OC, Russnes HG, Vollan HK, Frigessi A, Børresen-Dale AL.

Nat Rev Cancer. 2014 May;14(5):299-313. doi: 10.1038/nrc3721. Review.

PMID:
24759209
18.

Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.

Zhao X, Rødland EA, Sørlie T, Vollan HK, Russnes HG, Kristensen VN, Lingjærde OC, Børresen-Dale AL.

BMC Cancer. 2014 Mar 19;14:211. doi: 10.1186/1471-2407-14-211.

19.

Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma.

Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB.

Blood. 2014 Feb 13;123(7):1051-4. doi: 10.1182/blood-2013-07-512392.

20.

Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors.

Aure MR, Leivonen SK, Fleischer T, Zhu Q, Overgaard J, Alsner J, Tramm T, Louhimo R, Alnæs GI, Perälä M, Busato F, Touleimat N, Tost J, Børresen-Dale AL, Hautaniemi S, Troyanskaya OG, Lingjærde OC, Sahlberg KK, Kristensen VN.

Genome Biol. 2013 Nov 20;14(11):R126. doi: 10.1186/gb-2013-14-11-r126.

Supplemental Content

Loading ...
Support Center